Targeting bile‐acid signalling for metabolic diseases
Open accessThe DOI matches its Crossref record; 165 of the 169 references it cites were found in a registry or an index.
Abstract
Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.(157,158)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“After conjugation with either taurine or glycine, primary bile acids are released into the intestine to assist with lipid digestion and are recycled back into the liver (Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“By activating nuclear farnesoid X receptor (FXR) and plasma membrane TGR5 receptor, bile acids were shown to regulate systemic lipid, cholesterol, and glucose metabolism, as well as energy and immune homeostasis (Calmus and Poupon, 2014;de Aguiar Vallim et al., 2013;Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Research works printed but not linked: 1
- Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).
Cited by
Items 1,001–1,002 of 1,002
Bile resistance mechanisms in probiotics: From structural adaptation to metabolic regulation
Hu, J.-W., Guo, S.-J., Zhang, L.-W., & Guo, C.-F. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108282 · Cited by 5
The Microbiome, Metabolism, and Networks in Precision Nutrition
Mensah, G. E., Maseng, M. G., Allard, S., & Gilbert, J. A. (2024) · Precision Nutrition · doi:10.1016/b978-0-443-15315-0.00011-0 · Cited by 2
Metadata
- Authors
- Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K.
- Affiliations
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-08
- Volume
- 7
- Issue
- 8
- Pages
- 678-693
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2078810890
- Cited by
- 1,422
- References
- 169
- Citations by year
- 2026: 81 · 2025: 92 · 2024: 106 · 2023: 107 · 2022: 113 · 2021: 90 · 2020: 83 · 2019: 82 · 2018: 78 · 2017: 81 · 2016: 75 · 2015: 75 · 2014: 71 · 2013: 77 · 2012: 47
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Société Française de Nutrition
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Keywords
- bile acids, bile acid signaling, metabolic disorders, obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis, nonalcoholic steatohepatitis, therapeutic target, drug development
- MeSH terms
- Animals, Bile Acids and Salts, Humans, Metabolic Diseases, Signal Transduction, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.